A serene yet slightly surreal depiction of an elderly person sitting in a lush forest, bathed in sunlight. The person is holding a mushroom, symbolizing psilocybin. In the background, swirling patterns of light and color suggest altered states of consciousness, while their face expresses relief and hope.
Depression affects over 300 million people globally. Despite the widespread availability of antidepressants, many face limited efficacy and slow symptom relief. Psilocybin, a psychedelic found in mushrooms, offers a promising alternative.
“Psilocybin works differently than traditional antidepressants,” explains Dr. Metaxa. “It may enhance response rates, shorten the time to symptom relief, and reduce relapse rates.”
Several clinical trials show that psilocybin brings symptom relief within days, compared to weeks with conventional medications. Patients with secondary depression—depression resulting from other conditions—benefit the most.
How Does Psilocybin Work?
Psilocybin interacts with serotonin receptors, but unlike selective serotonin reuptake inhibitors (SSRIs), its effects can manifest within hours. Moreover, it has low addictive potential and can be safely administered under clinical supervision.
“Psilocybin’s potential lies in its ability to induce rapid, sustained antidepressant effects,” says Clarke. “But it’s essential to ensure proper screening and follow-up to avoid possible adverse reactions.”
Subgroup analyses reveal that older adults, patients with previous psychedelic use, and those with secondary depression experience greater symptom improvement. The Beck Depression Inventory, a self-reported scale, captures these changes more effectively.
The Science Behind the Meta-Analysis
The meta-analysis reviewed over 400 participants from nine randomized controlled trials. A significant improvement in depression scores was noted, with psilocybin outperforming placebo treatments. While the evidence shows promise, small sample sizes and varying study designs suggest the need for further large-scale trials.
“The heterogeneity of outcomes, particularly across self-reported scales and different patient types, highlights the importance of customized treatments,” says Metaxa.
A Step Towards Psychedelic Medicine
While psilocybin is not yet approved as a mainstream treatment, ongoing research may soon change that. Current studies focus on refining dosages, understanding long-term effects, and ensuring safe administration.
“With appropriate clinical supervision, psilocybin could transform the landscape of depression treatment,” says Clarke. “But the research must continue to solidify these early findings.”
Citation:
Metaxa A-M, Clarke M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. BMJ. 2024;385. doi:10.1136/bmj-2023-078084.
License:
This content is generated from the original article original article and it’s under Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
